In a National Eye Institute press release1 issued on May 5, 2013, with simultaneous online publication in JAMA,2 the results from the second phase of the Age-Related Eye Disease Study 2 (AREDS2) were announced. This press release was titled “NIH study provides clarity on supplements for protection against blinding eye disease,” and indeed in its first paragraph, the primary outcome was clearly stated: “The plant-derived antioxidants lutein and zeaxanthin also had no overall effect on [age-related macular degeneration (AMD)] when added to the combination; however, they were safer than the related antioxidant beta-carotene.” This study provided us with a striking example of a major clinical trial in which the primary outcome was negative, but yet its broader findings prompted substantial changes in the formulation of so-called eye vitamins that constitute a major market presence and are likely recommended by most eye care practitioners for a patient they determine to be at risk for developing neovascular AMD. The ability of companies to market their eye vitamins as providing an exact match to the AREDS2 formula is evidently important because we encounter such statements in venues ranging from our professional journals to television commercials. While some might say that the train has long since left the station, the purpose of this editorial is to critically evaluate the evidence underlying formulation changes that are under way or have already taken place.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 9
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.